Since its emergence at the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, has infected almost 700 million individuals and claimed ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Anticoagulation and/or antiplatelet therapy with a variety of agents does not prevent acute ...

LONDON — An expert group charged by the World Health Organization to investigate how the Covid-19 pandemic started released its final report Friday, reaching an unsatisfying conclusion: Scientists ...

Initial trials of low-dose lithium failed to improve long COVID symptoms, but new findings suggest higher doses could offer hope for patients suffering from fatigue and cognitive impairment. Study: ...

The effectiveness of repurposed medications for treating COVID-19 remains a critical area of investigation. A new analysis found that higher-dose fluvoxamine (Luvox), an antidepressant with ...

Nirmatrelvir/ritonavir (Paxlovid) failed to shorten COVID-19 symptom duration among people at standard risk for severe COVID-19 and among vaccinated people with at least one risk factor for severe ...

This summer has seen a large COVID wave—one which is showing the potential to be bigger than the 2023 winter wave was. The Joint Committee for Vaccination and Immunization (JCVI) have just published ...

Atea Pharmaceuticals’ antiviral has failed another COVID-19 trial, but the biotech still holds out hope the candidate has a future in hepatitis C. The oral nucleotide polymerase inhibitor ...

The spleen tyrosine kinase inhibitor fostamatinib (Tavalisse) did not improve outcomes in adults hospitalized with COVID-19 and hypoxemia, according to a phase III trial published in J AMA Network ...

GeNeuro reported (PDF) the near-total failure of its phase 2 long COVID trial Friday, telling investors it saw no effect on the primary endpoint and most secondary goals. The Swiss biotech responded ...

A review of death certificates in Oregon failed to turn up evidence of a greater risk of sudden cardiac death among individuals ages 16 to 30 who had recently received a COVID-19 vaccine, researchers ...